Search clinical trials for: Magrolimab

Total 38 results

Gilead Sciences

Terminated

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (ENHANCE-3)

Acute Myeloid Leukemia

United States, Spain, Germany, Israel, United Kingdom, Taiwan, Korea, Republic of, Australia, Belgium, Hong Kong, France, Netherlands, Italy, Canada, Austria, Czechia, Hungary, Norway, Poland, Switzerland
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Gilead Sciences

No longer available

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Gilead Sciences

Completed

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Solid Tumor

United States
Fisons

Completed

A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP

HIV Infections | Pneumonia, Pneumocystis Carinii

United States
University of California, San Francisco
Gilead Sciences

Suspended

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

Brain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, Pediatric

United States
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma | Chronic Lymphocytic Lymphoma

United States
Fisons

Completed

A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

HIV Infections | Pneumonia, Pneumocystis Carinii

United States
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Colorectal Cancer | Solid Tumor

United States
LyphoMed

Completed

A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

HIV Infections | Pneumonia, Pneumocystis Carinii

United States
Gilead Sciences
Merck KGaA, Darmstadt, Germany

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Ovarian Cancer

United States
M.D. Anderson Cancer Center

Withdrawn

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

B-cell Lymphoma | Large B-cell Lymphoma

United States
Hoffmann-La Roche
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Bladder Cancer | Urothelial Carcinoma

United States, Spain, Korea, Republic of, United Kingdom, Taiwan, France, Greece
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Insel Gruppe AG, University Hospital Bern
Swiss National Science Foundation; University of Bern

Recruiting

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma (MACOCUC-01)

Advanced Urothelial Carcinoma

Switzerland
Gilead Sciences

Terminated

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Hematological Malignancies

United States, United Kingdom
Gilead Sciences

Active, not recruiting

Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)

Solid Tumor

Spain, United Kingdom, United States, France, Poland
Novartis Pharmaceuticals

Withdrawn

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)

Head and Neck Squamous Cell Carcinoma

United States, France, Spain, Australia, Italy, Belgium, Hong Kong, Portugal, Poland, United Kingdom, Germany
Gilead Sciences
The Leukemia and Lymphoma Society

Active, not recruiting

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma

United States, Australia, United Kingdom
M.D. Anderson Cancer Center
Gilead Sciences

Suspended

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck | Head Neck

United States
Centre Hospitalier Universitaire de Besancon
Eli Lilly and Company; AstraZeneca

Completed

Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients (ExeQOL)

Quality of Life

France
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
Uwe Platzbecker
Gilead Sciences

Withdrawn

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS (MAGROLIC)

Acute Myeloid Leukemia | Myelodysplastic Neoplasm
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

Triple-Negative Breast Cancer

United States, United Kingdom, Australia, Hong Kong, Korea, Republic of, Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Relapsed Classical Hodgkin Lymphoma

United States
Gilead Sciences

Terminated

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2)

Acute Myeloid Leukemia

United States, Spain, Belgium, United Kingdom, Germany, Australia, Hong Kong, Denmark, France, Japan, Canada, Italy, Austria, Sweden, Switzerland
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Czechia, Canada
Gilead Sciences

Active, not recruiting

Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)

Metastatic Colorectal Cancer

United States, Spain, Australia, Hong Kong, France, Belgium, Canada, Puerto Rico, Germany, Italy
Gilead Sciences

Completed

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Myeloid Malignancies

United States, Australia, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

HIV Infections | Pneumonia, Pneumocystis Carinii

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Anatomic Stage IV Breast Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable Osteosarcoma

United States, Canada

Search clinical trials for: Magrolimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations